ULBI Ultralife Corporation

Delaware	000-20852	16-1387013
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
(315) 332-7100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, $0.10 par value per share	ULBI	NASDAQ
(Title of each class)	(Trading Symbol)	(Name of each exchange on which registered)

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Exhibit Number		Exhibit Description
99.1		Press Release of Ultralife Corporation dated July 25, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Date: July 25, 2024		ULTRALIFE CORPORATION
	By:	/s/ Philip A. Fain
		Philip A. Fain
		Chief Financial Officer and Treasurer

Exhibit 99.1

 

 

Ultralife Corporation Reports Second Quarter Results

 

 

NEWARK, N.Y. – July 25, 2024 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights:

 

●

Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the Company’s history for this segment

●

Gross profit of $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the 2023 second quarter

●

Operating income of $3.9 million, a 6.9% increase over the 2023 second quarter

●

GAAP EPS of $0.18 compared to $0.21 which included recognition of our Employee Retention Credit equivalent to $0.07 per share for the 2023 second quarter

●

Adjusted EBITDA of $5.4 million or 12.6% of sales versus $6.3 million or 14.7% last year, which included $1.5 million for our Employee Retention Credit

●

Backlog of $93.0 million exiting the second quarter

●

Debt reduction of $13.2 million, or 52.2%, to $12.1 million from $25.3 million at the end of the first quarter

 

“Ultralife’s second quarter results testify to the continued high demand for our products particularly from our government/defense and medical battery customers, the success of our initiatives to improve Battery & Energy Products’ gross margin, and our solid cash flow generation which we used to reduce our debt by over 50%,” said Mike Manna, President and Chief Executive Officer.  “Looking ahead to the second half of the year, our main priorities remain driving gross margin increases through material cost deflation, lean productivity, scrap reduction and price realization for both businesses, and expanding the opportunity funnels and customer wins for larger projects. We are optimistic that we are well positioned to sustain profitable growth and generate incremental cash flow that can be allocated to debt reduction and investments in strategic capital expenditures and accretive acquisitions.”

 

 

Second Quarter 2024 Financial Results

 

Revenue was $43.0 million compared to revenue of $42.7 million for the second quarter of 2023. Battery & Energy Products sales increased 8.3% to $36.7 million, compared to $33.9 million last year, reflecting increases of 30.5% in government/defense sales and 20.1% in medical battery sales, partially offset by a 10.9% decrease in oil & gas market sales. Communications Systems sales decreased 28.7% to $6.3 million compared to $8.8 million for the same period last year, primarily attributable to shipments in the 2023 period for orders which had been previously delayed by supply chain disruptions. Our total backlog exiting the second quarter was $93.0 million.

 

Gross profit was $11.6 million, or 26.9% of revenue, compared to $10.6 million, or 24.8% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin increased 480 basis points to 27.1%, compared to 22.3% last year, primarily due to higher cost absorption and more efficiencies resulting from our concerted effort to level-load production more evenly across the 2024 quarter, as well as improved price realization. Communications Systems gross margin was 25.6% compared to 34.5% last year, primarily due to product mix.

 

 

Operating expenses were $7.6 million, compared to $6.9 million for the 2023 second quarter, reflecting investments in new product development, the addition of sales resources to support future growth and executive bonus accruals which were not recognized in last year’s second quarter. Operating expenses were 17.8% of revenue compared to 16.2% of revenue for the year-earlier period.

 

Operating income was $3.9 million compared to $3.7 million last year. Driven by the 210-basis point gain in gross margin, operating margin increased to 9.1% compared to 8.6% last year.

 

Other income, reported below operating income, includes $0.2 million as a preliminary payment from our insurance carrier pertaining to the cyberattack which occurred in the first quarter of 2023. Other income for the second quarter of 2023 included an Employee Retention Credit (“ERC”) of $1.5 million under Section 2301 of the Coronavirus Aid, Relief and Economic Security Act of 2020 and the American Rescue Plan of 2021 which was filed with the Internal Revenue Service during that quarter.

 

Net income was $3.0 million, or $0.18 per diluted share on a GAAP basis, compared to net income of $3.3 million or $0.21 per diluted share for the second quarter of 2023. Adjusted EPS was $0.22 on a diluted basis for the second quarter of 2024, compared to $0.29 for the 2023 period. Adjusted EPS excludes the provision for deferred taxes which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future. Recognition of the ERC in the second quarter of 2023 increased GAAP and Adjusted EPS by $0.07 and $0.10, respectively, for that period.

 

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $5.4 million for the second quarter of 2024, or 12.6% of sales, compared to $6.3 million, or 14.7% of sales, for the year earlier period which included the ERC.

 

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EPS to EPS and adjusted EBITDA to net income attributable to Ultralife Corporation.

 

 

About Ultralife Corporation

 

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

 

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

 

 

Conference Call Information

 

Ultralife will hold its second quarter earnings conference call today at 8:30 AM ET.

 

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register.vevent.com/register/BI3ab77e4ff3d049f3b130d6d227043bba. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

 

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions or delays in our supply of raw materials and components due to business conditions, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

(Unaudited)

 

ASSETS
		June 30, 2024				December 31, 2023
Current Assets:
Cash		$	6,690			$	10,278
Trade Accounts Receivable, Net			31,055				31,761
Inventories, Net			41,392				42,215
Prepaid Expenses and Other Current Assets			4,650				5,949
Total Current Assets			83,787				90,203
Property, Plant and Equipment, Net			20,281				21,117
Goodwill			37,510				37,571
Other Intangible Assets, Net			14,646				15,107
Deferred Income Taxes, Net			9,088				10,567
Other Non-Current Assets			4,505				3,711
Total Assets		$	169,817			$	178,276
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable		$	9,691			$	11,336
Current Portion of Long-Term Debt			2,000				2,000
Accrued Compensation and Related Benefits			2,312				3,115
Accrued Expenses and Other Current Liabilities			6,570				7,279
Total Current Liabilities			20,573				23,730
Long-Term Debt, Net			9,978				23,624
Deferred Income Taxes			1,642				1,714
Other Non-Current Liabilities			4,279				3,781
Total Liabilities			36,472				52,849
Shareholders' Equity:
Common Stock			2,106				2,078
Capital in Excess of Par Value			191,388				189,160
Accumulated Deficit			(34,894	)			(40,754	)
Accumulated Other Comprehensive Loss			(3,895	)			(3,660	)
Treasury Stock			(21,492	)			(21,492	)
Total Ultralife Equity			133,213				125,332
Non-Controlling Interest			132				95
Total Shareholders’ Equity			133,345				125,427
Total Liabilities and Shareholders' Equity		$	169,817			$	178,276

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

		Three-Month Period Ended								Six-Month Period Ended
		June 30,				June 30,				June 30,				June 30,
		2024				2023				2024				2023
Revenues:
Battery & Energy Products		$	36,683			$	33,861			$	71,672			$	62,331
Communications Systems			6,300				8,831				13,238				12,277
Total Revenues			42,983				42,692				84,910				74,608
Cost of Products Sold:
Battery & Energy Products			26,730				26,318				52,733				48,276
Communications Systems			4,690				5,786				9,144				8,308
Total Cost of Products Sold			31,420				32,104				61,877				56,584
Gross Profit			11,563				10,588				23,033				18,024
Operating Expenses:
Research and Development			1,997				1,778				3,753				3,810
Selling, General and Administrative			5,649				5,145				11,300				10,523
Total Operating Expenses			7,646				6,923				15,053				14,333
Operating Income			3,917				3,665				7,980				3,691
Other (Expense) Income			(71	)			1,058				(527	))			564
Income Before Income Taxes			3,846				4,723				7,453				4,255
Income Tax Provision			853				1,375				1,556				1,242
Net Income			2,993				3,348				5,897				3,013
Net Income Attributable to Non-Controlling Interest			24				8				37				19
Net Income Attributable to Ultralife Corporation		$	2,969			$	3,340			$	5,860			$	2,994
Net Income Per Share Attributable to Ultralife Common Shareholders – Basic		$	.18			$	.21			$	.36			$	.19
Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted		$	.18			$	.21			$	.35			$	.19
Weighted Average Shares Outstanding – Basic			16,568				16,141				16,482				16,138
Weighted Average Shares Outstanding – Diluted			16,825				16,144				16,661				16,141

 

 

Non-GAAP Financial Measures

 

Adjusted EBITDA

 

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to U.S. Generally Accepted Accounting Principles (“GAAP”) financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)

 

		Three-Month Period Ended								Six-Month Period Ended
		June 30, 2024				June 30, 2023				June 30, 2024				June 30, 2023
Net Income Attributable to Ultralife Corporation		$	2,969			$	3,340			$	5,860			$	2,994
Adjustments:
Interest Expense, Net			418				440				938				864
Income Tax Provision			853				1,375				1,556				1,242
Depreciation Expense			789				760				1,529				1,522
Amortization Expense			227				227				455				436
Stock-Based Compensation Expense			159				154				320				293
Cyber-Insurance Policy Deductible			-				-				-				100
Adjusted EBITDA		$	5,415			$	6,296			$	10,658			$	7,451

 

 

Adjusted Earnings Per Share

 

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EPS

(In Thousands Except Per Share Amounts)

(Unaudited)

 

		Three-Month Period Ended
		June 30, 2024												June 30, 2023
		Amount				Per Basic Share				Per Diluted Share				Amount				Per Basic Share				Per Diluted Share
Net Income Attributable to Ultralife Corporation		$	2,969			$	.18			$	.18			$	3,340			$	.21			$	.21
Deferred Tax Provision			744				.04				.04				1,278				.08				.08
Adjusted Net Income		$	3,713			$	.22			$	.22			$	4,618			$	.29			$	.29
Weighted Average Shares Outstanding							16,568				16,825								16,141				16,144

 

		Six-Month Period Ended
		June 30, 2024												June 30, 2023
		Amount				Per Basic Share				Per Diluted Share				Amount				Per Basic Share				Per Diluted Share
Net Income Attributable to Ultralife Corporation		$	5,860			$	.36			$	.35			$	2,994			$	.19			$	.19
Deferred Tax Provision			1,394				.08				.08				888				.05				.05
Adjusted Net Income			7,254			$	.44			$	.43			$	3,882			$	.24			$	.24
Weighted Average Shares Outstanding							16,482				16,661								16,138				16,141

 

 

Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

pfain@ulbi.com

 

Investor Relations Contact:

LHA

Jody Burfening

(212) 838-3777

jburfening@lhai.com

 

v3.24.2

Document And Entity Information	Jul. 25, 2024
Document Information [Line Items]
Entity, Registrant Name	ULTRALIFE CORPORATION
Document, Type	8-K
Document, Period End Date	Jul. 25, 2024
Entity, Incorporation, State or Country Code	DE
Entity, File Number	000-20852
Entity, Tax Identification Number	16-1387013
Entity, Address, Address Line One	2000 Technology Parkway
Entity, Address, City or Town	Newark
Entity, Address, State or Province	NY
Entity, Address, Postal Zip Code	14513
City Area Code	315
Local Phone Number	332-7100
Title of 12(b) Security	Common Stock
Trading Symbol	ULBI
Security Exchange Name	NASDAQ
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity, Emerging Growth Company	false
Amendment Flag	false
Entity, Central Index Key	0000875657

---